Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would tick all my boxes for a great investment.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the biggest pieces of ASX news this week was the revelation that Chemist Warehouse shares might, at long last, be coming to the Australian stock market.

As we covered earlier this week, rumours are abounding that Chemist Warehouse might make its long-awaited ASX debut through some kind of 'reverse-merger' with ASX 300 healthcare stock Sigma Healthcare Ltd (ASX: SIG).

Sigma shares were quickly halted from trading amid these rumours, with the company confirming that "an announcement relating to a potential material transaction" is on the way. The shares have reportedly been halted until at least next week to "ensure the market is not trading on an uninformed basis while those discussions are ongoing".

So we don't yet know if Chemist Warehouse is indeed coming to the public markets. But I'm excited anyway. That's because Chemist Warehouse — if it does eventually list on the ASX — is a company that ticks almost all of my boxes as a potential investment.

Why am I keen to buy Chemist Warehouse shares?

Chances are most of us have visited a Chemist Warehouse somewhat recently. After all, this is a pharmacy chain that, according to a recent analysis from EY, "now commands over 50% market share in Australia".

Chemist Warehouse (at least in its current form) was founded back in 1993. So this is quite an accomplishment. Its controversial (yet evidently lucrative) business strategy of sidestepping Australia's strict pharmaceutical regulations that limit pharmacy proliferation has proved to be a winner.

My favourite investments usually have at least some of the following characteristics

  • a market leader in its industry
  • indication of the presence of a strong economic moat
  • operating in a defensive sector that is resistant to recessions and inflation

Chemist Warehouse seems to tick all three boxes.

It's clear that the company commands a leading position in the pharmaceutical industry if EY's analysis is to be believed.

Chemist Warehouse has strong brand power, as well as an obvious pricing advantage. Both of these moats have arguably allowed the company to expand at the expense of competitors.

And pharmaceuticals and medicines are highly defensive markets. When most of us are sick, we buy the medicines and pharmaceuticals that help us ride it out, regardless of economic conditions.

Private companies and public knowledge

Of course, I'll be doing some due diligence before I actually pick up the shares. Even now, Chemist Warehouse remains a private company. This means that details such as internal operations, financials and other information that public companies have to disclose remain unavailable to the public.

I'll want to get a good look at this information before buying up shares. I'll also want to buy the company at a price that makes sense. Not on whatever it trades at when it first lists.

But even so, I'll be excited to pick up some shares if and when the company eventually joins the ASX. Provided there are no red flags, of course.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »